WGS Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 5.69% compared to GeneDx Holdings's net margin of -22.5%. GeneDx Holdings's return on equity of -24.23% beat Delcath Systems's return on equity of -117.89%.

GeneDx Holdings has a consensus price target of $107.83, signalling upside risk potential of 9.72%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 94.81%. Given that Delcath Systems has higher upside potential than GeneDx Holdings, analysts believe Delcath Systems is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.729%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $95.6M, which are larger than Delcath Systems quarterly revenues of $15.1M. GeneDx Holdings's net income of $5.4M is higher than Delcath Systems's net income of -$3.4M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 8.65x versus 9.13x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 5.69% compared to GeneDx Holdings's net margin of -121.19%. GeneDx Holdings's return on equity of -24.23% beat Exact Sciences's return on equity of -34.11%.

GeneDx Holdings has a consensus price target of $107.83, signalling upside risk potential of 9.72%. On the other hand Exact Sciences has an analysts' consensus of $66.89 which suggests that it could grow by 58.29%. Given that Exact Sciences has higher upside potential than GeneDx Holdings, analysts believe Exact Sciences is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $95.6M, which are smaller than Exact Sciences quarterly revenues of $713.4M. GeneDx Holdings's net income of $5.4M is higher than Exact Sciences's net income of -$864.6M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 8.65x versus 2.82x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of 5.69% compared to GeneDx Holdings's net margin of 16.94%. GeneDx Holdings's return on equity of -24.23% beat Illumina's return on equity of -35.09%.

GeneDx Holdings has a consensus price target of $107.83, signalling upside risk potential of 9.72%. On the other hand Illumina has an analysts' consensus of $121.52 which suggests that it could grow by 65.27%. Given that Illumina has higher upside potential than GeneDx Holdings, analysts believe Illumina is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $95.6M, which are smaller than Illumina quarterly revenues of $1.1B. GeneDx Holdings's net income of $5.4M is lower than Illumina's net income of $187M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 8.65x versus 2.68x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of 5.69% compared to GeneDx Holdings's net margin of -14.37%. GeneDx Holdings's return on equity of -24.23% beat Star Equity Holdings's return on equity of -17.45%.

GeneDx Holdings has a consensus price target of $107.83, signalling upside risk potential of 9.72%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 429.38%. Given that Star Equity Holdings has higher upside potential than GeneDx Holdings, analysts believe Star Equity Holdings is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $95.6M, which are larger than Star Equity Holdings quarterly revenues of $17.1M. GeneDx Holdings's net income of $5.4M is higher than Star Equity Holdings's net income of -$2.5M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 8.65x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.